May 17, 2022 / 12:30PM GMT
Gregory James Renza - RBC Capital Markets, Research Division - Analyst
Good morning, everyone, and welcome back to the 2022 RBC Global Healthcare Conference. My name is Greg Renza, one of the senior biotechnology equity research analysts here, and we're pleased to have Exelixis with us today. And joining us from the company is the EVP and CFO, Chris Senner; as well as the SVP of Strategy, Andrew Peters. Guys, thanks for joining us this morning.
Christopher J. Senner - Exelixis, Inc. - Executive VP & CFO
Great. Thanks for having us. And excited to be here, sir, one of the few times we've been in public, not doing this via Zoom. So it's great to see everybody.
Gregory James Renza - RBC Capital Markets, Research Division - Analyst
Yes, absolutely. It's great to be in person again. And maybe, Chris, we can just kick off by having you give us on the audience a quick overview of Exelixis and what the pipeline is and what '22 has and will look like?
Christopher J. Senner - Exelixis, Inc. -
Exelixis Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers